Russell Investments Group
STOK icon

Russell Investments Group’s Stoke Therapeutics STOK Stock Holding History

Russell Investments Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
3,622
+5
+0.1% +$164 ﹤0.01% 3038
2025
Q4 		$115K Sell
3,617
-214
-6% -$6.43K ﹤0.01% 3013
2025
Q3 		$90K Sell
3,831
-11,919
-76% -$204K ﹤0.01% 3064
2025
Q2 		$179K Sell
15,750
-369
-2% -$3.5K ﹤0.01% 2680
2025
Q1 		$107K Buy
+16,119
New +$150K ﹤0.01% 2736
2024
Q3 		– Sell
-1,527
Closed -$20.6K – 3793
2024
Q2 		$20.6K Buy
+1,527
New +$20.6K ﹤0.01% 2933
2023
Q3 		– Sell
-1,382
Closed -$14.7K – 3621
2023
Q2 		$14.7K Hold
1,382
– – ﹤0.01% 2897
2023
Q1 		$11.5K Hold
1,382
– – ﹤0.01% 2865
2022
Q4 		$12.8K Hold
1,382
– – ﹤0.01% 2834
2022
Q3 		$17K Sell
1,382
-788
-36% -$12.6K ﹤0.01% 2823
2022
Q2 		$28K Buy
+2,170
New +$33K ﹤0.01% 2773
2022
Q1 		– Sell
-13,313
Closed -$319K – 2919
2021
Q4 		$319K Buy
+13,313
New +$318K ﹤0.01% 2588

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Russell Investments Group's STOK Position: Q1 2026 in Review

Russell Investments Group increased its Stoke Therapeutics (STOK) stake by 0.14% in Q1 2026, buying an estimated $164 and bringing the position to 3,622 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Russell Investments Group first reported a position in STOK in Q4 2021 and has held it in 12 quarters since. The position peaked at $319K in Q4 2021. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Russell Investments Group held 3,622 shares of Stoke Therapeutics worth $118K as of Q1 2026.
  • Russell Investments Group bought 5 Stoke Therapeutics shares in Q1 2026, an estimated $164.
  • Stoke Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3038 holding.
  • Russell Investments Group first reported a position in Stoke Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Russell Investments Group's Stoke Therapeutics position peaked at $319K in Q4 2021.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.